OcuSciences Inc.
Metabolic imaging to detect and monitor retinal disease
This article was originally published in Start Up
Executive Summary
OcuSciences Inc.'s OcuMet Beacon is a noninvasive and rapid diagnostic screening tool for retinal disease. The current ophthalmic standard of care, optical coherence tomography, evaluates structural change in retinal thickness or swelling after retinal damage has occurred, but OcuMet can provide a level of functional testing before damage occurs, which is especially important for latent diabetics or patients undiagnosed for retinal diseases.
You may also be interested in...
Korean Bioclusters Offer Tax, Other Incentives To Attract Global Firms, Talent
South Korea has formulated new detailed policy measures to support the formation of major bioclusters, which will offer tax and other incentives in a bid to lure foreign firms and talent.
CDC Panel Backs Pfizer’s Maternal RSV Vaccine But Leaves Room For AstraZeneca/Sanofi’s Beyfortus
Abrysvo is recommended for use in pregnant people 32-36 weeks gestation if administered from September to January. For infants whose mothers were not vaccinated in this window, nirsevimab is recommended for prevention of respiratory syncytial virus infection.
Jardiance Improves Double-Digit Growth Potential With US Approval In CKD
Boehringer expects Jardiance’s new chronic kidney disease indication to keep its sales growing by double-digit percentages over the coming years, aided by the drug’s ability to reduce hospitalizations.